Neurodegenerative Diseases Drugs Market set for rapid growth forecst 2020-2026| Key Players: Biogen Pfizer, Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Orion Pharma, UCB S.A, ACADIA Pharmace

The global neurodegenerative diseases drugs market's growth is expected to derive growth from the rising prevalence of neurodegenerative diseases especially among the aging population. Fortune Business Insights in a report, titled "Neurodegenerative Diseases Drugs: Global Market Analysis, Insights and Forecast, 2019-2026" offers valuable insights into the trends prevailing in the market. In 2018, the global market was valued at US$35,497.3 Mn and is projected to be worth US$ 62,786.2 Mn by 2026. At this pace, the global market is estimated to exhibit a healthy CAGR of 7.2% during the forecast duration.
Key Features of Neurodegenerative Diseases Drugs Market Report:
o Overview, Industry Life Cycle Analysis, Supply Chain Analysis
o Size, Trends, Growth Drivers, Constraints, SWOT Analysis, Forecast Analysis
o Competitive Landscapes: Market Share, Product Portfolio, New Product Launches, etc.
o Market attractiveness and Associated Growth Opportunities
o Strategic Growth Opportunities for the Existing and New Players
o Key Success Factors
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/neurodegenerative-diseases-drugs-market-100661
North America Dominates with Rising R&D Investments
In 2018, the North America market was valued at US$ 18,174.6 Mn and is anticipated to maintain its dominance throughout the forecast years. Neurodegenerative diseases have become more prevalent in the U.S. owing to an increasingly aging population. As per the Alzheimer's Association, around 5.4 million Americans were suffering from Alzheimer's in the year 2016. Moreover, this disease is more prevalent among people aged 65 years and above. As per research studies, approximately 30,000 people in the U.S. are projected to be suffering from another neurodegenerative disease called Huntington's disease. As per a study conducted by the Parkinson's Association in 2018, around 1.2 million people in the U.S are estimated to be suffering from Parkinson's disease by 2030. With the continuous rise in population, this disease is projected to double between 2018 and 2026. Considering these numbers, the market is likely to grow in North America. This, coupled with favorable healthcare reimbursement policies and rising research and development (R&D) investments is driving the market in this region.
The market in Asia Pacific is anticipated to report a considerable CAGR primarily on account of rising geriatric population.
Key Companies and Manufacturers Covered:
o Biogen
o Pfizer, Inc.
o F. Hoffmann-La Roche Ltd
o Merck & Co., Inc.
o Novartis AG
o Sanofi
o Teva Pharmaceutical Industries Ltd.
o Orion Pharma
o UCB S.A
o ACADIA Pharmaceuticals Inc.
o H. Lundbeck A/S
o Mitsubishi Tanabe Pharma Corporation

Biogen's Strategic Initiatives Helps the Company to Earn More Profits
In the year 2018, Biogen was dominating the global market. Neurodegenerative disease drug discovery and some important strategic decisions help the company to gain more attention. The launch of a drug called SPINRAZA and increasing sales of another drug called Tecfidera in 2018 helped the company to strengthen its product portfolio. Also, the company entered into a strategic partnership with F. Hoffmann-La Roche Ltd. to ensure robust distribution of drugs. This, together with the launch of two new drugs called Madopar and Ocrevus helped F. Hoffmann-La Roche Ltd. to gain the second position in the market.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/neurodegenerative-diseases-drugs-market-100661

Detailed Table of Content:
o Introduction
o Research Scope
o Market Segmentation
o Research Methodology
o Definitions and Assumptions
o Executive Summary
o Market Dynamics
o Market Drivers
o Market Restraints
o Market Opportunities
o Market Trends
o Key Insights
o Prevalence of Neurodegenerative Diseases - For Key Countreis, 2018
o Regulatory Scenario - For Key Countries
o Patent Snapshot
o New Product Launch
o Pipeline Analysis
o Key Industry Developments - Mergers, Acquisitions and Partnerships
o Global Neurodegenerative Diseases Drugs Market Analysis, Insights and Forecast, 2015-2026
o Key Findings / Summary
o Market Analysis, Insights and Forecast - By Drug Class
? Immunomodulators
? Interferons
? Decarboxylase Inhibitors
? Dopamine Agonists
? Others
o Market Analysis, Insights and Forecast - By Disease Indication
? Multiple Sclerosis
? Parkinson's Disease
? Alzheimer's Disease
? Spinal Muscular Atrophy (SMA)
? Others
o Market Analysis, Insights and Forecast - By Route of Administration
? Oral
? Injection
? Transdermal
o Market Analysis, Insights and Forecast - By Distribution Channel
? Hospital Pharmacy
? Retail Pharmacy
? Online Pharmacy
o Market Analysis, Insights and Forecast - By Region
? North America
? Europe
? Asia Pacific
? Latin America
? Middle East & Africa
TOC Continued....

About Us:

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Contact Us:
Fortune Business Insights(TM) Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.